WHO ICTRP trial
A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN…
EUCTR2007-007939-29-IT · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2007-007939-29-IT |
|---|---|
| Public title | A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS. - LB-MPT |
| Scientific title | A PHASE II,MULTI-CENTER, OPEN LABEL STUDY OF ORAL LBH589 PLUS MELPHALAN, PREDNISONE AND THALIDOMIDE (LB-MPT)IN ADVANCED, REFRACTORY MULTIPLE MYELOMA PATIENTS. - LB-MPT |
| Primary sponsor | FONDAZIONE NEOPLASIE SANGUE ONLUS |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Italy |
| Conditions | Patients with refractory or advanced Multiple Myeloma. MedDRA version: 9.1 Level: LLT Classification code 10051381 Term: Myeloma recurrence |
| Interventions | Trade Name: Thalidomide Pharmaceutical Form: Capsule, hard INN or Proposed INN: Thalidomide Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50- Pharmaceutical Form: Capsule, hard Concentration unit: mg… |
| Registration date | Oct 14, 2008 |
| Target size | 42 |
| Secondary IDs | CLBH589BIT01T |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: